Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

Name: Name: Name: Name: Ward: NHI: Seporal hota INITIATION – chronic renal failure Prerequisites (tick boxes where appropriate) Patient in chronic renal failure Prerequisites (tick boxes where appropriate) Patient not so not have diabetes mellitus and Glomerular filtration rate is less than or equal to 30mi/min or Patient has diabetes mellitus and Glomerular filtration rate is less than or equal to 45mi/min or Patient is on haemodialysis or pertioneal dialysis INITIATION – myelodysplasia* Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) Patient has a confirmed diagnosis of myelodysplasia (MDS) and Has had symptomatic anaemia with haemoglobin < 100g/L and is red cell transfusion-dependent and Patient has very low, low or intermediate risk MDS based on the WHO classification-based prognostic scoring system for myelodysplasite syndrome (WPS) and Other causes of anaemia such as B12 and folate deficiency have been excluded and Patient has a serum epoetin level of < 500 IU/L and The minimum necessary dose of epoetin would be used and will not exceed 80,000 lu per week CONTINUATION – myelodysplasia* Re-assessment required after 2 months Prerequisites (tick boxes where appropriate) The patient's transfusion requirement continues to be reduced with epoetin treatment and and Prequirement for myelodysplasia*	PRESCRIBER	PATIENT:				
Epoetin beta INITIATION – chronic renal failure Prerequisites (tick boxes where appropriate) Patient in chronic renal failure And Haemoglobin is less than or equal to 100g/L and Patient does not have diabetes mellitus and Glomerular filtration rate is less than or equal to 30mi/min or Patient tas diabetes mellitus and Glomerular filtration rate is less than or equal to 45mi/min or Patient tas on haemodialysis or peritoneal dialysis INITIATION – myelodysplasia* Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) Patient has a confirmed diagnosis of myelodysplasia (MDS) and Patient has not immed diagnosis of myelodysplasia (MDS) Has had symptomatic anaemia with haemoglobin < 100g/L and is red cell transfusion-dependent and Patient has very low, low or intermediate risk MDS based on the WHO classification-based prognostic scoring system for myelodysplastic syndrome (WPSS) of the causes of anaemia such as B12 and folate deficiency have been excluded and Patient has a serum epoetin level of < 500 IU/L and The minimum necessary dose of epoetin would be used and will not exceed 80,000 lu per week CONTINUATION – myelodysplasia* Re-assessment required after 2 months Prerequisites (tick boxes where appropriate) The patient's transfusion requirement continues to be reduced with epoetin freatment	Name:	Name:				
INITIATION – chronic renal failure Prerequisites (tick boxes where appropriate) Patient in chronic renal failure and Haemoglobin is less than or equal to 100g/L and Patient does not have diabetes mellitus and Glomerular filtration rate is less than or equal to 30ml/min or Patient has diabetes mellitus and Glomerular filtration rate is less than or equal to 45ml/min or Patient is on haemodialysis or peritoneal dialysis INITIATION – myelodysplasia* Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) Patient has a confirmed diagnosis of myelodysplasia (MDS) and Has had symptomatic anaemia with haemoglobin < 100g/L and is red cell transfusion-dependent and Patient has very low, low or intermediate risk MDS based on the WHO classification-based prognostic scoring system for myelodysplastic syndrome (WPSS) and Other causes of anaemia such as B12 and folate deficiency have been excluded and Patient has a serum epoetin level of < 500 IU/L and The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week CONTINUATION – myelodysplasia* Re-assessment required after 2 months Prerequisites (tick boxes where appropriate)	Ward:	NHI:				
Prerequisites (tick boxes where appropriate) Patient in chronic renal failure and Haemoglobin is less than or equal to 100g/L and Patient does not have diabetes mellitus and Glomerular filtration rate is less than or equal to 30ml/min or Patient has diabetes mellitus and Glomerular filtration rate is less than or equal to 45ml/min or Patient is on haemodialysis or peritoneal dialysis INITIATION – myelodysplasia* Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) Patient has a confirmed diagnosis of myelodysplasia (MDS) and Patient has very low, low or intermediate risk MDS based on the WHO classification-based prognostic scoring system for myelodysplastic syndrome (WPSS) and Other causes of anaemia such as B12 and folate deficiency have been excluded and Patient has a serum epoetin level of < 500 IU/L The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week CONTINUATION – myelodysplasia* Re-assessment required after 2 months Prerequisites (tick boxes where appropriate)	Epoetin beta	1				
Haemoglobin is less than or equal to 100g/L Patient does not have diabetes mellitus and Glomerular filtration rate is less than or equal to 30ml/min or Patient has diabetes mellitus and Glomerular filtration rate is less than or equal to 45ml/min or Patient is on haemodialysis or peritoneal dialysis INITIATION - myelodysplasia* Re-assessment required after 12 months						
Haemoglobin is less than or equal to 100g/L O	O	O Patient in chronic renal failure				
INITIATION – myelodysplasia* Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) Other causes of anaemia such as B12 and folate deficiency have been excluded and Patient has a serum epoetin level of < 500 IU/L The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week CONTINUATION – myelodysplasia* Re-assessment required after 12 months Patient has a serum epoetin level of < 500 IU/L The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week CONTINUATION – myelodysplasia* Re-assessment required after 2 months Prerequisites (tick boxes where appropriate) The patient's transfusion requirement continues to be reduced with epoetin treatment and of the patient's transfusion requirement continues to be reduced with epoetin treatment		Haemoglobin is less than or equal to 100g/L				
Patient has diabetes mellitus and Glomerular filtration rate is less than or equal to 45mi/min or Patient is on haemodialysis or peritoneal dialysis INITIATION – myelodysplasia* Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) Patient has a confirmed diagnosis of myelodysplasia (MDS) and Has had symptomatic anaemia with haemoglobin < 100g/L and is red cell transfusion-dependent and Patient has very low, low or intermediate risk MDS based on the WHO classification-based prognostic scoring system for myelodysplastic syndrome (WPSS) and Other causes of anaemia such as B12 and folate deficiency have been excluded and Patient has a serum epoetin level of < 500 IU/L and The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week CONTINUATION – myelodysplasia* Re-assessment required after 2 months Prerequisites (tick boxes where appropriate) The patient's transfusion requirement continues to be reduced with epoetin treatment and and The patient's transfusion requirement continues to be reduced with epoetin treatment		and				
INITIATION – myelodysplasia* Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) O Patient has a confirmed diagnosis of myelodysplasia (MDS) and Has had symptomatic anaemia with haemoglobin < 100g/L and is red cell transfusion-dependent and Patient has very low, low or intermediate risk MDS based on the WHO classification-based prognostic scoring system for myelodysplastic syndrome (WPSS) and Other causes of anaemia such as B12 and folate deficiency have been excluded and Patient has a serum epoetin level of < 500 IU/L and The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week CONTINUATION – myelodysplasia* Re-assessment required after 2 months Prerequisites (tick boxes where appropriate) The patient's transfusion requirement continues to be reduced with epoetin treatment and The patient's transfusion requirement continues to be reduced with epoetin treatment	or					
INITIATION – myelodysplasia* Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) Patient has a confirmed diagnosis of myelodysplasia (MDS) and Has had symptomatic anaemia with haemoglobin < 100g/L and is red cell transfusion-dependent and Patient has very low, low or intermediate risk MDS based on the WHO classification-based prognostic scoring system for myelodysplastic syndrome (WPSS) and Other causes of anaemia such as B12 and folate deficiency have been excluded and Patient has a serum epoetin level of < 500 IU/L and The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week CONTINUATION – myelodysplasia* Re-assessment required after 2 months Prerequisites (tick boxes where appropriate) The patient's transfusion requirement continues to be reduced with epoetin treatment and The patient's transfusion requirement continues to be reduced with epoetin treatment	or	Glomerular filtration rate is less than or equal to 45ml/min				
Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) Patient has a confirmed diagnosis of myelodysplasia (MDS) and Has had symptomatic anaemia with haemoglobin < 100g/L and is red cell transfusion-dependent and Patient has very low, low or intermediate risk MDS based on the WHO classification-based prognostic scoring system for myelodysplastic syndrome (WPSS) and Other causes of anaemia such as B12 and folate deficiency have been excluded and Patient has a serum epoetin level of < 500 IU/L and The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week CONTINUATION – myelodysplasia* Re-assessment required after 2 months Prerequisites (tick boxes where appropriate) The patient's transfusion requirement continues to be reduced with epoetin treatment and		O Patient is on haemodialysis or peritoneal dialysis				
Has had symptomatic anaemia with haemoglobin < 100g/L and is red cell transfusion-dependent and Patient has very low, low or intermediate risk MDS based on the WHO classification-based prognostic scoring system for myelodysplastic syndrome (WPSS) and Other causes of anaemia such as B12 and folate deficiency have been excluded and Patient has a serum epoetin level of < 500 IU/L and The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week CONTINUATION – myelodysplasia* Re-assessment required after 2 months Prerequisites (tick boxes where appropriate) The patient's transfusion requirement continues to be reduced with epoetin treatment and	Re-assessment required after 12 months					
Has had symptomatic anaemia with haemoglobin < 100g/L and is red cell transfusion-dependent Patient has very low, low or intermediate risk MDS based on the WHO classification-based prognostic scoring system for myelodysplastic syndrome (WPSS) and Other causes of anaemia such as B12 and folate deficiency have been excluded and Patient has a serum epoetin level of < 500 IU/L The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week CONTINUATION – myelodysplasia* Re-assessment required after 2 months Prerequisites (tick boxes where appropriate) The patient's transfusion requirement continues to be reduced with epoetin treatment and	and	Patient has a confirmed diagnosis of myelodysplasia (MDS)				
Patient has very low, low or intermediate risk MDS based on the WHO classification-based prognostic scoring system for myelodysplastic syndrome (WPSS) and Other causes of anaemia such as B12 and folate deficiency have been excluded and Patient has a serum epoetin level of < 500 IU/L and The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week CONTINUATION – myelodysplasia* Re-assessment required after 2 months Prerequisites (tick boxes where appropriate) The patient's transfusion requirement continues to be reduced with epoetin treatment and	0	Has had symptomatic anaemia with haemoglobin < 100g/L and is red cell transfusion-dependent				
Other causes of anaemia such as B12 and folate deficiency have been excluded Patient has a serum epoetin level of < 500 IU/L and The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week CONTINUATION – myelodysplasia* Re-assessment required after 2 months Prerequisites (tick boxes where appropriate) The patient's transfusion requirement continues to be reduced with epoetin treatment and	0	Patient has very low, low or intermediate risk MDS based on the WHO classification-based prognostic scoring system for myelodysplastic syndrome (WPSS)				
Patient has a serum epoetin level of < 500 IU/L The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week CONTINUATION – myelodysplasia* Re-assessment required after 2 months Prerequisites (tick boxes where appropriate) The patient's transfusion requirement continues to be reduced with epoetin treatment and	0	Other causes of anaemia such as B12 and folate deficiency have been excluded				
The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week CONTINUATION – myelodysplasia* Re-assessment required after 2 months Prerequisites (tick boxes where appropriate) The patient's transfusion requirement continues to be reduced with epoetin treatment and	0	Patient has a serum epoetin level of < 500 IU/L				
Re-assessment required after 2 months Prerequisites (tick boxes where appropriate) The patient's transfusion requirement continues to be reduced with epoetin treatment and		The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week				
and	Re-assessmen	t required after 2 months				
	and	The patient's transfusion requirement continues to be reduced with epoetin treatment				
Transformation to acute myeloid leukaemia has not occurred and	and	Transformation to acute myeloid leukaemia has not occurred				
The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week	O	The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week				

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRESCRIBER			PATIENT:		
Name	e:		Name:		
Ward	:		NHI:		
Epoetin beta - continued					
INITIATION – all other indications					
Prerequisites (tick boxes where appropriate)		(tick boxes where appropriate)			
	O	Haematologist			
	O For use in patients where blood transfusion is not a viable treatment alternative				
	and	*Note: Indications marked with * are unapproved indications			